Mangoceuticals, Inc. Cash and Restricted Cash
Mangoceuticals, Inc. (MGRX) had Cash and Restricted Cash of $228.69 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $228.69K.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $174.56K.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.49M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $481.28K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $228.69K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $174.56K 10-Q · filed 2026-05-19 |
| 2025-12-31 | $1.49M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $481.28K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $101.02K 10-Q · filed 2026-08-13 |
| 2025-03-31 | $76.50K 10-Q · filed 2026-05-19 |
| 2024-12-31 | $58.65K 10-Q · filed 2026-08-13 |
| 2024-09-30 | $73.91K 10-Q · filed 2025-11-14 |
| 2024-06-30 | $490.24K 10-Q/A · filed 2025-11-14 |
| 2024-03-31 | $15.30K 10-Q · filed 2025-05-15 |
| 2023-12-31 | $739.01K 10-K · filed 2026-04-01 |
| 2023-09-30 | $1.24M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $2.95M 10-Q · filed 2024-08-14 |
| 2022-12-31 | $682.86K 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |